Shareholders Sue Biopharma Co. Over Alzheimer's Drug Trials
Investors in Annovis Bio Inc. have filed a proposed class action claiming the Pennsylvania biopharmaceutical company artificially inflated its stock value this spring by misrepresenting the success of its drug trials...To view the full article, register now.
Already a subscriber? Click here to view full article